Clinical trial
Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS)
NCT06850038 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS)
- Lead sponsor
- Ipsen
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- April 22, 2025
- Completion date
- November 30, 2030
- Enrollment
- 30 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.